Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[In-111]-Trillium Compounds and PTI-122 in Metastatic Prostate Cancer
NCT05773703Phase 1Completed
- Sponsor
- Ratio Therapeutics
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of indium-111-labeled Trillium compound and PTI-122 in Metastatic Prostate Cancer (mPC) (3 arms), sponsored by Ratio Therapeutics. Primary endpoints: Amount of radiotracer absorbed by tumor at 168 hours, Amount of radioactivity in blood at 168 hours and 1 more. Started Dec 2022; status: completed.
02
Drugs
indium-111-labeled Trillium compoundPTI-122
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT05773703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773703.